Defined Term Location. Issuing Party Section 12.1(b) Joint Sponsored Design/Preclinical Collaboration Technology Section 9.2(d)(iii) JRC Section 3.2(a) Losses Section 13.5(a) [***] License Section 4.1 [***] Section 4.1 Option Fee Section 8.2 Pfizer Compound Improvement Section 9.2(c) Pfizer Indemnitees Section 13.5(c) Pfizer Option Notice Section 4.1 Pfizer Option Period Section 4.1 Pfizer Sponsored Design/Preclinical Collaboration Technology Section 9.2(c)(i) [***] License Section 4.1 [***] Section 4.1 Product Specific Patent Section 10.1(c) Program Lead Section 3.1 Receiving Party Section 12.1(a) Release Section 12.1(b) Replacement Period Section 2.2(c) Reviewing Party Section 12.1(b) Royalty Term Section 8.8(b) Sole Sponsored Design/Preclinical Collaboration Technology Section 9.2(c)(i) Targeted Nanoparticle Section 1.1 Supply Agreement Section 6.1 Term Section 14.1
Appears in 2 contracts
Sources: Research, Option and License Agreement (BIND Therapeutics, Inc), Research, Option and License Agreement (BIND Therapeutics, Inc)